The impact of the US food and drug administration chlorofluorocarbon ban on out-of-pocket costs and use of albuterol inhalers among individuals with asthma

JAMA Internal Medicine

Volumn 175, Issue 7, 2015, Pages 1171-1179

  Jena, Anupam B ^a,b,c   Ho, Oliver ^c   Goldman, Dana P ^b,d   Karaca Mandic, Pinar ^b,e  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NATIONAL BUREAU OF ECONOMIC RESEARCH   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROFLUOROCARBON; SALBUTAMOL; BRONCHODILATING AGENT;

ADULT; AGE DISTRIBUTION; ARTICLE; ASTHMA; CHILD; CHLOROFLUOROCARBON BAN; COMORBIDITY; DRUG COST; DRUG UTILIZATION; ENVIRONMENTAL PLANNING; ENVIRONMENTAL PROTECTION; FEMALE; FOOD AND DRUG ADMINISTRATION; HOSPITALIZATION; HUMAN; INHALER; INSURANCE; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; PRESCRIPTION; PRIORITY JOURNAL; SEX DIFFERENCE; UNITED STATES; ECONOMICS; HEALTH CARE COST; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; NEBULIZER; UTILIZATION;

ADMINISTRATION, INHALATION; ALBUTEROL; ASTHMA; BRONCHODILATOR AGENTS; CHILD; CHLOROFLUOROCARBONS; FEMALE; HEALTH EXPENDITURES; HUMANS; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS;

EID: 84937485230     PISSN: 21686106     EISSN: 21686114     Source Type: Journal    
DOI: 10.1001/jamainternmed.2015.1665     Document Type: Article

References (33)

1. Food and Drug Administration, HHS. Use of ozone-depleting substances: removal of essential-use designations: final rule. Fed Regist. 2005;70(63):17167-17192.
2. Hendeles L, Colice GL, Meyer RJ. Withdrawal of albuterol inhalers containing chlorofluorocarbon propellants. N Engl J Med. 2007;356(13):1344-1351.
3. Harrison E. Unlikely victims of banning CFCs: asthma sufferers. Scientific American. August 1, 2008.
4. Rosenthal E. The soaring cost of a single breath. New York Times. October 13, 2013:A1.
5. Tarkan L. Rough transition to a new asthma inhaler. New York Times. May 13, 2008.
6. Food and Drug Administration, HHS. Use of ozone-depleting substances: removal of essential-use designations. Fed Regist. 2004;69: 33602-33618.
7. Selby JV, Fireman BH, Swain BE. Effect of a copayment on use of the emergency department in a health maintenance organization. N Engl J Med. 1996;334(10):635-641.
8. Newhouse JP, ManningWG, Morris CN, et al. Some interim results from a controlled trial of cost sharing in health insurance. N Engl J Med. 1981;305 (25):1501-1507.
9. Chernew ME, Rosen AB, Fendrick AM. Value-based insurance design. Health Aff (Millwood). 2007;26(2):w195-w203.
10. Chandra A, Gruber J, McKnight R. Patient cost-sharing and hospitalization offsets in the elderly. Am Econ Rev. 2010;100(1):193-213.
11. Goldman DP, Joyce GF, Escarce JJ, et al. Pharmacy benefits and the use of drugs by the chronically ill. JAMA. 2004;291(19):2344-2350.
12. Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA. 2007;298(1):61-69.
13. Karaca-Mandic P, Jena AB, Joyce GF, Goldman DP. Out-of-pocket medication costs and use of medications and health care services among children with asthma. JAMA. 2012;307(12):1284-1291.
14. UngarWJ, Kozyrskyj A, Paterson M, Ahmad F. Effect of cost-sharing on use of asthma medication in children. Arch Pediatr Adolesc Med. 2008;162(2): 104-110.
15. UngarWJ, Paterson JM, Gomes T, et al. Relationship of asthma management, socioeconomic status, and medication insurance characteristics to exacerbation frequency in children with asthma. Ann Allergy Asthma Immunol. 2011;106(1):17-23.
16. Leibowitz A, ManningWG Jr, Keeler EB, Duan N, Lohr KN, Newhouse JP. Effect of cost-sharing on the use of medical services by children: interim results from a randomized controlled trial. Pediatrics. 1985;75(5):942-951.
17. Johnson TJ, RimszaM, JohnsonWG. The effects of cost-shifting in the State Children's Health Insurance Program. Am J Public Health. 2006;96 (4):709-715.
18. Bethell CD, Read D, Blumberg SJ, Newacheck PW. What is the prevalence of children with special health care needs? toward an understanding of variations in findings and methods across three national surveys. Matern Child Health J. 2008;12(1): 1-14.
19. Goldman DP, Joyce GF, Karaca-Mandic P. Varying pharmacy benefits with clinical status: the case of cholesterol-lowering therapy. Am J Manag Care. 2006;12(1):21-28.
20. Joyce GF, Escarce JJ, Solomon MD, Goldman DP. Employer drug benefit plans and spending on prescription drugs. JAMA. 2002;288(14):1733-1739.
21. Joyce GF, Goldman DP, Karaca-Mandic P, Zheng Y. Pharmacy benefit caps and the chronically ill. Health Aff (Millwood). 2007;26(5):1333-1344.
22. Abrevaya J. The equivalence of two estimators of the fixed effects logit model. Econ Econ Lett. 1997;55(1):41-44.
23. Katz E. Bias in conditional and unconditional fixed effects logit estimation. Polit Anal. 2001;9(4): 379-384.
24. Urbano FL. Review of the NAEPP 2007 Expert Panel Report (EPR-3) on asthma diagnosis and treatment guidelines. J Manag Care Pharm. 2008; 14(1):41-49.
25. Birnbaum HG, Ivanova JI, Yu AP, et al Asthma severity categorization using a claims-based algorithm or pulmonary function testing. J Asthma. 2009;46(1):67-72.
26. Kynyk JA, Mastronarde JG, McCallister JW. Asthma, the sex difference. Curr Opin Pulm Med. 2011;17(1):6-11.
27. Lloyd SA. Stratospheric ozone depletion. Lancet. 1993;342(8880):1156-1158.
28. West SK, Duncan DD, Mu?oz B, et al. Sunlight exposure and risk of lens opacities in a population-based study: the Salisbury Eye Evaluation project. JAMA. 1998;280(8):714-718.
29. Eklund AG, Altshuler SL, Altshuler PC, et al. Stratospheric ozone, global warming, and the principle of unintended consequences: an ongoing science and policy story. J AirWaste Manag Assoc. 2013;63(11):1235-1244.
30. Kogan MD, Newacheck PW, Blumberg SJ, et al. Underinsurance among children in the United States. N Engl J Med. 2010;363(9):841-851.
31. Kogan MD, Newacheck PW, Honberg L, Strickland B. Association between underinsurance and access to care among children with special health care needs in the United States. Pediatrics. 2005;116(5):1162-1169.
32. Cantrell CR, Eaddy MT, Shah MB, Regan TS, Sokol MC. Methods for evaluating patient adherence to antidepressant therapy: a real-world comparison of adherence and economic outcomes. Med Care. 2006;44(4):300-303.
33. Nwokeji ED, Bohman TM,Wallisch L, et al. Evaluating patient adherence to antidepressant therapy among uninsured working adults diagnosed with major depression: results of the Texas Demonstration to Maintain Independence and Employment study. Adm Policy Ment Health. 2012;39(5):374-382.